Kyntra Bio (KYNB) Other Operating Expenses (2019 - 2026)
Kyntra Bio (KYNB) posted Other Operating Expenses of $4.1 million for Q1 2026, up 1376.98% sequentially from $278000.0 in Q4 2025, and up 1529.37% YoY from $252000.0 in Q1 2025.
Kyntra Bio (KYNB) Other Operating Expenses (2019 - 2026) Analysis & Trends
Kyntra Bio has reported Other Operating Expenses for 8 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Other Operating Expenses rose 1529.37% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 179.78% YoY) and the FY2025 annual result came in at $556000.0, down 96.43% from the prior year.
- Other Operating Expenses rose to $4.1 million in Q1 2026 per KYNB's latest filing, from $278000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $21.3 million in Q1 2024 and troughed at -$9.5 million in Q4 2023.
- A 5-year average of $2.6 million and a median of $3.5 million in 2023 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2023 and 2026: Other Operating Expenses sank 292.47% in 2023, then jumped 1529.37% in 2026.
- Over 5 years, Other Operating Expenses stood at $4.9 million in 2022, then tumbled by 292.47% to -$9.5 million in 2023, then jumped by 38.33% to -$5.8 million in 2024, then jumped by 104.76% to $278000.0 in 2025, then jumped by 1376.98% to $4.1 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $4.1 million, $278000.0, and -$58000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 4.11 Mn |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | -58,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Mar 31, 2025 | 252,000.00 |
| Dec 31, 2024 | -5.85 Mn |
| Sep 30, 2024 | -75,000.00 |
| Jun 30, 2024 | 140,000.00 |
| Mar 31, 2024 | 21.34 Mn |
| Dec 31, 2023 | -9.48 Mn |
| Sep 30, 2023 | 4.24 Mn |
| Jun 30, 2023 | 5.71 Mn |
| Mar 31, 2023 | 3.49 Mn |
| Dec 31, 2022 | 4.93 Mn |
| Sep 30, 2022 | 4.31 Mn |
| Jun 30, 2022 | 6.81 Mn |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 3.27 Mn |